QuidelOrtho Corp. 10-Q Summary: Q3 2025
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for QuidelOrtho Corporation for the period ended September 28, 2025. The company operates in the diagnostics sector with reportable segments in North America, EMEA, and China. The reporting period includes significant strategic shifts, including the wind-down of the U.S. donor screening portfolio, the discontinuation of the Savanna molecular platform, and a major debt refinancing.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $699.9 | $727.1 | $2,006.6 | $2,075.1 |
| Net Loss | $(733.0) | $(19.9) | $(1,001.1) | $(1,873.6) |
| Operating Loss | $(704.8) | $15.0 | $(852.9) | $(1,860.5) |
| Adjusted EBITDA (Total Segments) | $316.2 | $330.1 | $883.9 | $903.3 |
| Cash and Equivalents | $98.1 | $144.0 | $98.1 | $144.0 |
| Total Debt (Current + Long-term) | $2,659.0 | $2,483.1 | $2,659.0 | $2,483.1 |
| Operating Cash Flow (9M) | $(26.7) | $19.3 | $(26.7) | $19.3 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 4% in Q3 and 3% for the nine months ended September 28, 2025. This was primarily driven by a 47% drop in Donor Screening revenue (due to the planned U.S. wind-down) and a 20% decline in Point of Care revenue (driven by lower sales of SARS antigen assays).
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $700.7 million in Q3 2025, representing a full impairment of goodwill for the EMEA, China, and Latin America reporting units. This was triggered by a sustained decline in stock price and market capitalization.
- Restructuring Charges: Restructuring, integration, and other charges totaled $39.6 million in Q3 and $234.6 million for the nine months. Significant portions relate to the "Savanna Exit" (discontinuation of the Savanna platform) and the "Optimization Plan" (cost-reduction initiatives).
- Debt Refinancing: On August 21, 2025, the company entered a new Credit Agreement, refinancing prior debt with $1.15 billion in Term Loan A, $1.45 billion in Term Loan B, and a $700 million Revolving Credit Facility. This resulted in a $5.1 million loss on extinguishment of debt.
Guidance, Outlook, and Risks
- Outlook: Management expects demand for respiratory products to fluctuate based on seasonal factors (flu, RSV, COVID-19) and competitive pressures. The company aims to deliver improved financial results through cost-savings initiatives and new product introductions.
- Optimization Plan: The company launched a multi-year cost-reduction plan in Q2 2025, expecting cumulative pre-tax charges of approximately $100 million through 2027, with net cost savings of ~$50 million.
- Legal Proceedings: The company faces a putative class action lawsuit regarding COVID-19 test sales and the Savanna RVP4 assay. Additionally, a final judgment was entered in Q3 2025 regarding a supplier dispute, requiring a $10.8 million payment (accrued in Q3).
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 28, 2025, due to material weaknesses previously reported. Remediation efforts are ongoing, including ERP system migrations.
- Tariffs: Recent U.S. tariffs on imports from various countries are incurring incremental costs for parts, materials, and shipping, though the company has thus far offset these through operating measures.
Investor Verification Checklist
- Goodwill Impairment Assumptions: Verify the discounted cash flow and market multiple assumptions used to justify the $700.7 million impairment charge.
- Debt Covenants: Confirm continued compliance with the new Credit Agreement's leverage ratio (max 4.50x) and interest coverage ratio (min 3.00x) given the recent losses.
- Respiratory Revenue Volatility: Monitor the trajectory of respiratory product sales (currently 14-16% of revenue) as they remain highly seasonal and competitive.
- Restructuring Execution: Track the progress of the "Optimization Plan" and "Savanna Exit" to ensure projected cost savings are realized without further revenue erosion.
- Internal Control Remediation: Review the timeline and effectiveness of the remediation plan for material weaknesses in internal controls over financial reporting.